Skip to content

A Trial of Rigid Versus Semirigid Thoracoscopy in the Evaluation of Exudative Pleural Effusions

A Randomized Controlled Trial of Rigid Versus Semirigid Thoracoscopy in the Evaluation of Exudative Pleural Effusions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01726556
Acronym
RISE
Enrollment
70
Registered
2012-11-15
Start date
2011-04-30
Completion date
2012-12-31
Last updated
2013-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pleurisy With Effusion

Keywords

Pleural effusion, Semirigid thoracoscopy, Rigid thoracoscopy

Brief summary

Rigid thoracoscopy is an established procedure for the performance of pleural biopsies for undiagnosed pleural effusions. The semirigid thoracoscope is a relatively new instrument designed for the same purpose which is claimed to be more user-friendly. The two devices have not been compared in a head-to-head trial in published literature. The investigators attempt to conduct a randomised comparative trial between the two devices.

Interventions

DEVICERigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)

Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany

DEVICESemirigid thoracoscope (model LTF-160Y1, Olympus, Japan)

Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with an exudative (as defined by Light's criteria) pleural effusion of unknown etiology after a microbiological (namely gram stain and acid fast bacillus stain) and cytological examination

Exclusion criteria

* Significant hypoxemia on room air * Hemodynamic instability * Significant cardiac disease (known myocardial infarction in last 6 weeks or presence of unstable angina) * Refractory cough * Lack of pleural space due to adhesions * Uncorrected coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic yield of thoracoscopic biopsy by intention to treat analysis3 monthsThe proportion of patients where thoracoscopic pleural biopsy yielded a diagnosis that was consistent with the present clinical picture and the further follow-up of the patients, would be calculated and compared between the two arms

Secondary

MeasureTime frameDescription
Yield of biopsies successfully completed3 monthsThe diagnostic yield of only those procedures would be considered separately where a biopsy could be successfully done and compared between the two arms
Complications3 monthsNumber of major and minor complications encountered in the two arms
Scar sizeAt the end of the procedureScar size (in mm) in the longest axis
Biopsy sizeAt the end of the procedureBiopsy size (in mm) in the longest axis

Other

MeasureTime frameDescription
Use of sedation and analgesia during the procedureAt the end of procedureThe quantity of drugs used for sedation and analgesia during the procedure would be recorded and compared between the two arms
Operators' experience characteristicsAt the end of the procedureThese would include, on a numerical scale of 0 to 100, the operator's grading of the following characteristics: quality of thoracoscopic image, ease of maneuvering, ease of taking a biopsy and the operator's expectation that the biopsy will reveal a definitive histological diagnosis

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026